Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
WST - West Pharmaceutical Services, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$407.00
DETAILS
HIGH:
$447.00
LOW:
$365.00
MEDIAN:
$407.50
CONSENSUS:
$407.00
UPSIDE:
12.38%
Stock News
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. $WST Shares Sold by HB Wealth Management LLC
HB Wealth Management LLC lowered its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 28.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,709 shares of the medical instruments supplier's stock after selling 1,858 shares during the quarter.
Analyzing West Pharmaceutical Services (NYSE:WST) and Acutus Medical (NASDAQ:AFIB)
West Pharmaceutical Services (NYSE: WST - Get Free Report) and Acutus Medical (NASDAQ: AFIB - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends. Volatility and Risk West Pharmaceutical Services has
Benjamin Edwards Inc. Grows Position in West Pharmaceutical Services, Inc. $WST
Benjamin Edwards Inc. grew its stake in West Pharmaceutical Services, Inc. (NYSE: WST) by 47.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,322 shares of the medical instruments supplier's stock after buying an additional 1,720 shares
West Pharmaceutical Services, Inc. (NYSE:WST) Receives Average Recommendation of “Moderate Buy” from Brokerages
West Pharmaceutical Services, Inc. (NYSE: WST - Get Free Report) has earned an average rating of "Moderate Buy" from the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the
7,730 Shares in West Pharmaceutical Services, Inc. $WST Bought by Caisse de depot et placement du Quebec
Caisse de depot et placement du Quebec purchased a new stake in West Pharmaceutical Services, Inc. (NYSE: WST) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,730 shares of the medical instruments supplier's stock, valued at approximately $2,775,000. Several
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.
3,700 Shares in West Pharmaceutical Services, Inc. $WST Purchased by Barbara Oil Co.
Barbara Oil Co. acquired a new stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,700 shares of the medical instruments supplier's stock, valued at approximately $1,339,000. Other institutional investors and hedge funds
Advisors Capital Management LLC Acquires New Shares in West Pharmaceutical Services, Inc. $WST
Advisors Capital Management LLC bought a new stake in West Pharmaceutical Services, Inc. (NYSE: WST) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,270 shares of the medical instruments supplier's stock, valued at approximately $1,533,000. A number
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.
Conestoga SMid Cap Composite Q2 2026 Portfolio Review
West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.
West Pharmaceutical Services, Inc. $WST Holdings Increased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 461,462 shares of the medical instruments supplier's stock after acquiring an additional 24,102 shares during
West Pharmaceutical Services, Inc. $WST Shares Acquired by Bank of Nova Scotia
Bank of Nova Scotia increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 337.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,323 shares of the medical instruments supplier's stock after buying an additional 50,402 shares
West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift
West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.
Price Targets
West Pharmaceutical assumed with a Buy at UBS
$415.00
(was $338.06)
UBS
West Pharmaceutical price target raised to $425 from $410 at Evercore ISI
$425.00
(was $333.12)
Evercore ISI
West Pharmaceutical initiated with an Outperform at BNP Paribas
$447.00
(was $353.71)
BNP Paribas
West Pharmaceutical price target raised to $365 from $325 at Morgan Stanley
$365.00
(was $353.68)
Morgan Stanley
West Pharmaceutical price target raised to $410 from $390 at Evercore ISI
$410.00
(was $359.27)
Daniel Markowitz
·
Evercore ISI
West Pharmaceutical price target raised to $390 from $350 at KeyBanc
$390.00
(was $365.00)
KeyBanc
Barclays upgrades West Pharmaceutical on 'material' upside to estimates
$400.00
(was $319.75)
Luke Sergott
·
Barclays
West Pharmaceutical price target raised to $315 from $285 at Morgan Stanley
$315.00
(was $306.39)
Morgan Stanley
West Pharmaceutical price target raised to $310 from $275 at Barclays
$310.00
(was $306.16)
Barclays
West Pharmaceutical price target lowered to $340 from $355 at UBS
$340.00
(was $246.60)
Dan Leonard
·
UBS
West Pharmaceutical price target raised to $315 from $310 at Deutsche Bank
$315.00
(was $247.49)
Deutsche Bank
West Pharmaceutical price target lowered to $265 from $325 at Barclays
$265.00
(was $243.61)
Luke Sergott
·
Barclays
West Pharmaceutical price target lowered to $295 from $365 at Jefferies
$295.00
(was $249.97)
David Windley
·
Jefferies
West Pharmaceutical price target lowered to $320 from $390 at Evercore ISI
$320.00
(was $237.88)
Daniel Markowitz
·
Evercore ISI
West Pharmaceutical initiated with an Equal Weight at Morgan Stanley
$285.00
(was $274.14)
Morgan Stanley
West Pharmaceutical price target raised to $325 from $275 at Barclays
$325.00
(was $293.62)
Barclays
West Pharmaceutical price target raised to $355 from $320 at UBS
$355.00
(was $307.25)
Dan Leonard
·
UBS
West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
$345.00
(was $304.74)
Justin Bowers
·
Deutsche Bank
West Pharmaceutical price target raised to $390 from $350 at Evercore ISI
$390.00
(was $309.28)
Daniel Markowitz
·
Evercore ISI
West Pharmaceutical added to 'Tactical Outperform' list at Evercore ISI
$350.00
(was $268.07)
Evercore ISI